Key Highlights
- Co-Diagnostics (CODX) shares increased 9.43% to reach $2.90 during Friday’s premarket session
- CoSara Diagnostics, the firm’s Indian partnership, secured distribution rights across Bangladesh, Pakistan, Nepal, and Sri Lanka
- This territorial agreement positions CoSara to target approximately $13 billion in addressable market value throughout South Asia
- Key offerings planned for these markets include the PCR Pro® point-of-care system and SARAGENE® diagnostics suite, subject to local regulatory clearance
- A virtual distributor engagement session is scheduled for Q2 2026, followed by an in-person training event that summer
Shares of Co-Diagnostics (CODX) posted significant premarket gains on Friday, advancing 9.43% to $2.90 following news of a strategic territorial expansion agreement for the company’s South Asian operations.
CoSara Diagnostics Pvt. Ltd., a collaborative venture between Co-Diagnostics and Ambalal Sarabhai Enterprises Limited (ASE Group), has finalized an agreement expanding its commercial footprint throughout South Asia. The partnership now includes distribution and commercial rights in Bangladesh, Pakistan, Nepal, and Sri Lanka.
According to the company’s internal market research combined with external industry data, this geographic expansion brings CoSara’s potential market opportunity in the region to approximately $13 billion.
The territorial agreement focuses on bringing two primary diagnostic solutions to these markets: the CoSara PCR Pro® point-of-care testing platform and the comprehensive SARAGENE® diagnostic portfolio. Commercial availability in each country will depend on obtaining necessary regulatory authorizations.
CoSara is actively developing its distribution infrastructure throughout these four nations. Current priorities include navigating regulatory approval processes, identifying target healthcare segments, and forging relationships with regional distribution partners.
Executive Perspectives on Regional Growth
Mohal Sarabhai, Chief Executive Officer of CoSara, emphasized that South Asian markets demonstrate significant and expanding demand for convenient, non-invasive molecular diagnostic solutions. He highlighted tuberculosis screening, HPV detection, and respiratory pathogen testing as particularly important application areas for the region.
Dwight Egan, CEO of Co-Diagnostics, characterized the expansion as aligned with the company’s broader infrastructure-focused approach. He explained that the strategy involves establishing local manufacturing capabilities and distribution networks ahead of product launches — a methodology the company is implementing across the United States, South Asian territories, and Middle East and North Africa regions.
Egan indicated that this groundwork is intended to enable Co-Diagnostics to scale its PCR point-of-care testing platform across international markets efficiently.
To facilitate distributor recruitment and engagement, CoSara has outlined a phased outreach plan. The initiative begins with a virtual information and orientation session targeting Q2 2026, followed by an in-person distributor conference and comprehensive training program scheduled for later that summer.
Current Market Position
Prior to Friday’s premarket rally, CODX shares were trading near their 52-week low point of $2.04. The 9.43% gain pushed the stock to $2.90 in early trading.
Investors should note that the PCR Pro® platform and associated diagnostic products remain under FDA evaluation and are not currently authorized for commercial distribution.
In recent months, Co-Diagnostics announced it secured a Japanese patent protecting its PCR platform technology. The company also recently resolved NASDAQ listing compliance concerns, regaining full compliance with exchange requirements.
The $13 billion total addressable market figure represents company projections based on proprietary analysis and third-party market intelligence. Actual revenue generation will ultimately depend on securing regulatory approvals and successfully executing distribution partnerships across all four newly added territories.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
